4,125 Johnson & Johnson $JNJ Shares Sold by Rockland Trust Co.

Rockland Trust Co. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,352 shares of the company’s stock after selling 4,125 shares during the quarter. Rockland Trust Co.’s holdings in Johnson & Johnson were worth $19,684,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. Outlook Capital Management LLC bought a new stake in shares of Johnson & Johnson in the second quarter worth about $28,000. Matrix Trust Co grew its position in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the period. Montgomery Financial Services LLC bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $43,000. Hyposwiss Advisors SA acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $42,000. Finally, Polaris Financial Partners bought a new position in Johnson & Johnson in the third quarter valued at approximately $56,000. Institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 87,569 shares of company stock worth $23,064,544 in the last quarter. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $2.00 during trading on Monday, hitting $254.03. 3,741,572 shares of the stock were exchanged, compared to its average volume of 7,973,521. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a fifty day moving average price of $266.37 and a 200-day moving average price of $248.40. The stock has a market capitalization of $612.19 billion, a price-to-earnings ratio of 29.43, a price-to-earnings-growth ratio of 2.52 and a beta of 0.21. Johnson & Johnson has a 1-year low of $182.94 and a 1-year high of $281.07.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. Johnson & Johnson’s revenue was up 6.6% on a year-over-year basis. During the same period last year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities analysts predict that Johnson & Johnson will post 11.54 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is presently 62.11%.

Analyst Ratings Changes

A number of brokerages recently weighed in on JNJ. HSBC upped their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a report on Wednesday, July 15th. Citigroup reissued a “buy” rating on shares of Johnson & Johnson in a research report on Monday. Wells Fargo & Company upped their price target on Johnson & Johnson from $272.00 to $282.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $282.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $275.87.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.